Pacific Edge raised NZ$25.4 million (about $15.1 million) via a share placement to support operations and pursue Medicare coverage for its Cxbladder Triage assay. The company said it expects Medicare contractor Novitas to release a draft Local Coverage Determination (LCD) for hematuria evaluation that includes coverage for Triage, potentially also next-generation Triage Plus, before September. It pointed to earlier Medicare non-coverage for Cxbladder and said the decision drove reduced US test volumes and revenue in FY2026. Pacific Edge also signaled additional share issuance capacity of up to NZ$6 million at the same NZ$0.17 per-share price, with support from existing institutional and other investors.